<html xmlns="http://www.w3.org/1999/xhtml"><head>
        <meta http-equiv="Content-Type" content="text/html; charset=utf-8">
        <meta name="viewport" content="width=device-width, height=device-height, initial-scale=0.5, minimum-scale=0.5, user-scalable=yes, maximum-scale=2.0, target-densitydpi=device-dpi" />
				<meta name="robots" content="all"/>
        <meta name="description" content="description">
        <meta name="keywords" content="">
        <title>Page 373 - MIMS April 2020 E4</title>
<style type="text/css">
<!--
body {
	margin-left: 0px;
	margin-top: 0px;
	margin-right: 0px;
	margin-bottom: 0px;
}
  
#container {margin:50px auto;padding:0px;width:910px;}
#left-button{ width:90px; height:100%;float:left }
#middle{ width:730px; margin:0px; float: left;}
#right-button{ width:90px; float:left;}
html, body, div, ul, li, dl, dt, dd, h1, h2, h3, h4, h5, h6, form, input, dd,select, button, textarea, iframe, table, th, td { margin: 0; padding: 0; }
img { border: 0 none; displayblock}
span,ul,li,image{ padding:0px; margin:0px; list-style:none;}
#top-title{ width:714px; margin-bottom:10px; float:left; padding:0px 8px}
#top-title2{ width:320px;  float:right;}
#content{ width: 730px; float:left;float:left;word-wrap: break-word;}
#content-top{ width:730px; background-image:url(images/top_bg.jpg); height:56px; background-repeat:no-repeat; float:left;}
#content-top1{ width:70%; padding:16px 0px 0px 30px; font-family:Arial, Helvetica, sans-serif; font-size:24px; color:#636363;float:left;}
#content-top2{ width:60px; float:right; padding:25px 30px 0px 0px;font-family:Arial, Helvetica, sans-serif; font-size:11px; color:#2f2f2f; font-weight:bold; text-align:right}
#content-middle{ width:730px; background-image:url(images/middle_bg.jpg); background-repeat:repeat-y;float:left;}
#content-middle1{ width:475px; padding:25px 0px 25px 35px; font-family:Arial, Helvetica, sans-serif; font-size:12px; color:#636363; line-height:150%;float:left;}
#content-middle2{  padding:7px; float:right; margin:25px 35px 0px 0px; border:solid 1px #c8c8c9; background-color:#FFF; text-align:center}
#content-bottom{ width:730px; background-image:url(images/bottom_bg.jpg); background-repeat:no-repeat; height:58px;float:left;}
#content-bottom2{ width:110px; height:42px; margin:0px auto; padding-top:4px;}
#input{ width:58px; height:20px; background-color:#FFF; border:solid 1px #dfdfe0; color:#636363; text-align:center; font-size:11px;}
.font1{ font-family:Arial, Helvetica, sans-serif; font-size:10px; color:#2f2f2f;}
.font1 a:link{
	text-decoration: none;
    color:#2f2f2f;

}
.font1 a:visited{
	text-decoration: none;
    color:#2f2f2f;
	
}
.font1 a:hover{
	color: #2f2f2f;
	text-decoration: underline;

}



.text-container {
padding: 20px;
color: #333;
margin-top: 24px;
line-height: 22px;
border-top-left-radius: 3px;
border-top-right-radius: 3px;
}

.use-as-video {
float: right;
padding-left: 20px;
}
.cc-float-fix:before, .cc-float-fix:after {
content: "";
line-height: 0;
height: 0;
width: 0;
display: block;
visibility: hidden;
}
.use-as-video-img {
cursor: pointer;
position: relative;
width: 320px;
height: 180px;
}
.use-as-video-title {
font-size: 15px;
font-weight: bold;
color: #000000;
padding-bottom: 5px;
}
-->
</style>
<script type="text/javascript">
<!--
function MM_preloadImages() { //v3.0
  var d=document; if(d.images){ if(!d.MM_p) d.MM_p=new Array();
    var i,j=d.MM_p.length,a=MM_preloadImages.arguments; for(i=0; i<a.length; i++)
    if (a[i].indexOf("#")!=0){ d.MM_p[j]=new Image; d.MM_p[j++].src=a[i];}}
}

function MM_swapImgRestore() { //v3.0
  var i,x,a=document.MM_sr; for(i=0;a&&i<a.length&&(x=a[i])&&x.oSrc;i++) x.src=x.oSrc;
}

function MM_findObj(n, d) { //v4.01
  var p,i,x;  if(!d) d=document; if((p=n.indexOf("?"))>0&&parent.frames.length) {
    d=parent.frames[n.substring(p+1)].document; n=n.substring(0,p);}
  if(!(x=d[n])&&d.all) x=d.all[n]; for (i=0;!x&&i<d.forms.length;i++) x=d.forms[i][n];
  for(i=0;!x&&d.layers&&i<d.layers.length;i++) x=MM_findObj(n,d.layers[i].document);
  if(!x && d.getElementById) x=d.getElementById(n); return x;
}

function MM_swapImage() { //v3.0
  var i,j=0,x,a=MM_swapImage.arguments; document.MM_sr=new Array; for(i=0;i<(a.length-2);i+=3)
   if ((x=MM_findObj(a[i]))!=null){document.MM_sr[j++]=x; if(!x.oSrc) x.oSrc=x.src; x.src=a[i+2];}
}
//-->
</script>
</head>

<body onload="MM_preloadImages('images/next2.png','images/previous2.png')">
<div id="container">
<div id="left-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page372.html"><img src="images/previous_big.png" width="90" height="80" /></a></p>
</div>
<div id="middle">
  <div id="top-title"><span class="font1">Basic HTML Version</span>
    <div id="top-title2">
      <table width="100%" border="0" align="right" cellpadding="0" cellspacing="0">
        <tr>
        	<td width="66%"> </td>
          <td width="35%" style="display:none" align="right"><img src="images/content.png" width="19" height="16" /></td>
          <td width="31%" style="display:none" class="font1"><a href="">Table of Contents</a></td>
          <td width="6%"><img src="images/view.png" width="19" height="16" /></td>
          <td width="28%" class="font1"><a href="../../MIMS April 2020 E4.html#p=373">View Full Version</a></td>
        </tr>
      </table>
    </div>
  </div>
  <div id="content">
     <div id="content-top">
        <div id="content-top1">Page 373 - MIMS April 2020 E4</div>
        <div id="content-top2">P. 373</div>
     </div>
     <div id="content-middle">
     	
     	  <div class="text-container">
    <div class="use-as-video cc-float-fix">
      <a style="text-decoration: none;" href="../../MIMS April 2020 E4.html#p=373"><img src="../thumb/373.jpg" /></a>
    </div>

    <p class="use-as-video-title"></p>
    <pre style="white-space:pre-line"><code>336 / 2020-04                                                                 Biologicals - 26
   may be pres.& hepatit. B will not be prevent., cons. benef.-risk ratio   Dosage: Admin.IMI in deltoid reg., admin.SC in thrombocytopaen./  Contraindications: IV admin.,
   in delay.vaccinat.in cases of sev.act.infect.  bleed.disords., HIV infect. doesn’t. contraindic.its use.  Side effects: Loc.& cutan.reacts., headache, lightheadedn., naus.,
                                Prim.vaccinat. sched: Sched consists of 3 dos.in tot. given at 6, 10   flush, fev., chills, backache,
   HERCEPTIN, Roche [P/S]       & 14 wks.of age. Booster recomm. in 2  yr.to ensure long term protect.  Warnings and special precautions: IMI with bleed.disords.,
                                                nd
   Trastuzumab                  Contraindications: Hypersens.signs aft.prev. admin. of Hib vac.,   emerg.meas.to be avail.for poss. anaphylax., consid.risk-benef.ratio
   Indications: Powd.for injection & SC inj: Metastat. breast adeno-  IV admin.   in pts.with hist. of IgA defic./sev.anaphylact.reacts.to plasma prods.,
   carcinoma where tumours overexpress. HER2: as monother.where   Side effects: V.common: Appet. loss., unusual cry./ restlessn, di-  infect.dis.also of unknown/emerging vir. transmiss. cannot be tot.
   at least 2 chemother. regim.for metastat.dis.receiv./in combin. with   arrh., fev., redn.at inj.site. Common: Vomit., pain & swell.at inj.site.   excl., consid.appropr. rout. vaccinat. bef.admin.human bld./plasma
   paclitaxel/docetaxel where no chemother. for metastat.dis.receiv./  Unknown: Allerg.reacts., angioed., hypotonic-hyporesponse epis.,   prod.to prev. poss.infect.dis.transmiss., safety in pregn.& lactat.not
   in combinat. with aromatas.inhibit.in horm.-recept.posit. metastat.   convuls., syncope/vasovag. inj respons., somnol., apnoea, urticar.,   est.although clin.exper.sugg.no harmf. effs.
   breast Ca, HER2 positiv.early breast adenocarcinoma: treatm.follow.  rash, extens. swell. of vaccinat.limb, inj.site indurat.  Interactions: Delay live virus vaccinat.for 3 mnths. aft.treatm., tran-
   surg./chemother. & radiother.if applic./follow adjuv.chemother.with   Warnings and special precautions: Not effect. against dis.due   sit.rise of var.passiv. transf.antibod.aft.inj.of immunoglobul.may give
   doxorubic. & cyclophosphamide in combinat.with docetaxel. Only   to other types of. H.influenz./other organ.caus.meningit.or sept. dis.,   mislead.positiv.res.in serologic.test.,
   admin.where tumours have eith. HER2 overexpress./HER2 gene   postpone in sev. febr.illn., pregn./lactat.as safety & effic.not est.,
   ampliciat.determ. by accur.& valid.assay/have HER2 overexpress.at   limit.immune respon.to tetan. tox.compon.may occur but vaccin.  KEYTRUDA, MSD [P/S]
   a 3+ lev. as determin.by immunohistochem.  with HIBERIX alone not substit. for tetan.vaccin., potent.apnoea risk   Pembrolizumab
   Powd.for injection only: HER2 positiv.metastat. gastric-adenocar-  in prem.infts., have proced.in place to avoid injury from faints, adre-  Indications: Unresect./metastat.melanoma., 2nd line treatm./ great-
   cinoma of stomach/gastro-oesophag. junct.in combinat.with capecit-  nal.to be readily avail.for immed.use in case of anaphylax., supervis.   er for treatm.of pts with advanc. NSCLC whose tumours expr.PD-L1 as
   abine/ 5-fluorouracil & cisplat.where no prior anti cancer treatm. for   pt.for 30 mins.aft.vaccin., antigen detect. may not have diagnost.val.  determin.by a validat. test & have receiv.platinum-contain. chemother.
   metastat.dis.receiv.only where HER2 overexpress.defin.by IHC2+ &   in suspect. Hib dis. within 1-2 wks of vaccin., admin other inj.vacc.at   (S4) SOL.FOR INFUS, 50/30.1/0957. 25 mg/ml
   confirmat.silver in situ hybirdisat.(SISH)/fluorescence in situ hybirdi-  diff.inj.sites, adeq.respon.may not be achiev.in pts.receiv.immunosu-  723729-001: 25 mg/ml, 1x 4 ml vial, R40 993,61
   sat. (FISH)/IHC3+ results.   press.ther./ immunodefic.     Dosage: Admin.as IV infus.over 30 mins., do not co-admin. other
   (S4) POWD.FOR INJ, 34/26/0419, 34/34/0420                  meds.through the same infus.line.
   884055-001: 440 mg, sngl.vials+dil., R8 500,00  INFANRIX, GSK [P/S]  Recomm. dos.: 2mg/kg every 3 wks.until dis. progress./ unac-
   (S4) 600 MG SUBCUT.INJ: 48/26/1244  Diphtheria toxoid not less than 30 IU, tetanus toxoid not less than   cept.toxic.
   723199-001: 600 mg/5 ml vial, 1, R9 100,00  40 IU, pertussis toxoid (PT) 25 µg, filamentous haemagglutinin (FHA)   Dose modificat.: refer to prod.lit.
   For further details refer to manufact.prod.lit.  25 µg, pertactin 8 µg, recombin.HBsAg prot. 10 µg, D-antigen type   Admin.corticoster.for immune-mediat.reacts. where indicat. Clinical.
                                1(Mahoney) polio virus 40 units, D-antigen type 2(MEF-1) polio virus   stable pts.with init.evid.of dis. progress. should remain on treatm.un-
   HEXAXIM, Sanofi-Aventis [P/S]  8 units, D-antigen type 3(Saukett) polio virus 32 units, purif.capsul.  til dis. progress. confirm.
   Diphtheria toxoid ≥ 20 U, tetanus toxoid ≥ 40 IU, pertussis toxoid   polysaccharide of Hib 10 µg/0,5 ml dos.  Contraindications: Pregn. & lactat., safety & effic. in childr.&lt; 18
   (PT) 25 µg, filamentous haemagglutinin (FHA) 25 µg, D-antigen type   Indications: Prim.& booster vaccinat.against diphth./ tetanus/  yrs of age not yet est.
   1(Mahoney) polio virus 40 units, D-antigen type 2(MEF-1) polio vi-  pertussis/hepatit.B/poliomyelit.& haemophil. influenzae type b in   Side effects: Fatig., rash, prurit., arthralg., bld. disords., immune
                                                 st
   rus 8 units, D-antigen type 3(Saukett) polio virus 32 units, Hepatit.B   infts.from 6 wks and infts.who receiv.1  dos.hepatit.B vacc.at birth.  thrombocytopen.purpura, haemolyt. anaem., infus.relat.react., hy-
   surface antigen 10 µg, Haemophilus influenza type b (Hib) polysac-  (S2) HEXA INJ, 36/30.1/0347  perthyroid., hypothyroid., hypophysit., adren.insuffic., thyroidit., decr.
   charide, conjugat.to tetanus protein [tetanus protein:22-36 µg]12 µg   707285-001: 1xsyr.& vial, R484,22  appet., type 1 diab.mellit., hyponatraem., hypokalaem., hypocalcaem.,
   (express.as amount of polysaccharide)/0,5 ml.  Dosage: Do not use in accord.with EPI(SA) sched. of 6,10 & 14 wks.  insomn., CNS disords., dry eye, uveit., hypertens., pneumonit., dyspn.,
   Indications: Prim.& booster vaccinat.of infts.from 6 wks.against   unless prim.dos.of register. hepatit. B vacc.has been admin.at birth.  cough, GI disords., hepatit., sev. skin reacts., vitiligo, dermatit.acneif.,
   diphtheria./ tetanus/pertussis/ hepatit B/ poliomyelit./& invas.infects.  Prim.vacc.sched: 3 dos.of 0,5 ml admin.by deep IMI at interv.of   dry skin, erythema, eczema, lichen.keratos., psorias., alopec., ery-
   caus.by Hib type b (such as meningit./septicaem./cellulit./ arthrit./   at least 1 mnth.start.betw.2-3 mnths. May be used as a replacem.  thema nodos., dermatit., hair col. chang., papule, arthralg., myosit.,
                                                        nd
   epiglottit./pneumopathy/osteomyelit.)  for supplem. hepatit.B vacc.dos.from age of 6 wks.If a 2  hepatit.   musculoskelet. /extremity pain, arthrit., tenosynovit., nephrit., fatig,
   (S2) INJ, 46/30.1/0447       B vacc.dos.requir.bef.this age, monoval. hepatit.B should be used.  asthen., oed., pyrex., influenza like illn., chills
   719637-001: 1x pre-fill.syr., R538,40  Booster dos: May be giv.at least 6 mnths.aft.last prim. dos.& pref.  Warnings and special precautions:. Pts.with EGFR/ ALK
   719637-002: 10x pre-fill.syr., R5,384,06  bef.18 mnths.of age. Giv.in accord. with offic.recommendat.but must   genom. tumour aberrat.to receiv. approv. ther.prior to receiv.Keytru-
   Dosage: Prim.vacc.sched: 3 dos.of 0,5 ml (e.g. 6,10,14 wks;   incl.at least the Hib conjug.compon. Infts.to receiv. booster vaccinat.  da., monit.pts for pneumonit.: admin.corticoster.for Grade 2/great.
   2,3,4 mnths; 3,4,5  mnths; 2,4,6 mnths.) admin.by IM inj.at interv.of   with other licens.vacc.accord.to offic.loc.recommendat.where avail.  events; withhold dose for Grade 2 pneumonit.; perman. discont.if
   at least 4 wks. in accord.with offic.recommendat. All vaccin. sched.  Contraindications: Hypersens.reacts.to prev. diphther./ tetanus/  Grade 3/4/recurr.Grade 2 events dev., monit.for colit.: admin.corti-
   can be used wheth.or not a dos.of Hepatit.B vacc.was giv.at birth.   pertuss./hepatit.B/polio or Hib vacc., encephalopathy of unknown   coster.for Grade 2/great. events; withhold.dos.for Grade 2/3 colit.
   If hepatit.B dos. was giv.at birth Hexaxim may be used for supplem.   aetiology within 7 days of prev.pertussis vaccinat., intravasc./ in-  & perman. discont.for Grade 4 colit., monit.for chang. in liv.funct.&
   dos.of Hepatit.B vacc.from age 6 wks. Monoval. hepatit.B vacc.to be   traderm. admin., adults.  sympts.of hepatit.: admin. corticoster. & withhold.dos./discont.bas.
   used if a 2  dos.of hepatit.B vacc. requir.bef.this age.  Side effects: Very comm: Appet.loss, irritabil., abnorm. cry., rest-  on sev.of elev. liv. enzymes., monit.for chang.in ren.funct.: admin.
       nd
   Booster dos: Aft.vaccin.with 3 dos. (e.g.6,10, 14 wks; 2,3,4 mnths.;   lessn., pain, redn., loc.swell.at inj. site, fev.≥ 38°C, fatig. Comm:   corticoster.for Grade 2/great.events & withhold dose for Grade 2
   3,4,5 mnths; 2,4,6 mnths)of Hexaxim, a booster dos.should be giv.pref.  Nervousn., vomit., diarrh., prurit., fev.&gt; 39,5°C, inj.site reacts. incl.  nephrit.; perman. discont. if Grade 3/4 dev., monit.for hypophysit.:
     nd
   dur.2  yr.of life at least 6 mnths.aft.the last prim.dos. Booster dos.to be   indurat. Uncomm: URTI, somnol., cough, diffuse swell.of inj.limb/  admin. corticoster.to treat second.adren.insuffic. & other hormone
   giv.in accord.with offic. recommendat. but a minim.dos.of Hib must be   adjac.joint. Rare: Bronchitis, rash. Very rare: Convuls.with/-out fev.,   replacem.as clinic.indicat.; withhold dos.for Grade 2 hypophysit.,
   admin. Hexaxim or Pentaxim can be consid.(in accord. with the offic.  dermatit., urticar. Unknown: Lymphadenopathy, thrombocytopen., al-  withhold./ discont. if Grade 3/4 dev., monit.for hyperglycaem./
   recommendat.)for booster dos. when subj.is primed against diphth./  lerg.react, collapse/shock-like state, apn., angioneurot. oed., extens.  other S&S of diab.: admin. insul. for type 1 diab.& withhold dos.in
                                swell.reacts., vesicles at inj.site.
   pertuss./ tetanus/ hep.B/poliomyelit./invas.infects.caus.by Hib.  sev. hyperglycaem. until metabol.contr.achiev., monit. for chang.
   This vacc.may be consid.until 5 yrs.  Warnings and special precautions: Appropr. medic. treatm.to   in thyr.funct.(at treatm.init./dur.& as clinic. indicat.) & S&S of thyr.
                                be avail.in case of anaphylax., discont. pertussis vaccin.if child exper.
   Contraindications: Intravasc.inj., women of child-bear.age, sev.  disords.: manage symptomatic. & withhold./discont.if Grade 3/ 4
   allerg.react.hist.to any compon. of vacc./any pertuss.cont.vacc.aft.  encelopathy of unknown orig.occur.with.7 days follow.prev. pertuss.  hyperthyroid. dev., continuat.of dos.may be consid. for Grade 3/ 4
                                vacc., postpone in ac.sev.febrile illn., obt. prev. vaccinat.medic.hist.&
   prev.admin.of the vacc. or a vacc.cont.same compon., postpone in   endocrinopathy that improv.to Grade 2/ low. & controll.with horm.
   mod.to sev.febr.&/ac.dis., encephalopathy within 7 days of prev.  exam.clinic., eval. merits of subseq.dos. in case of temp.≥40°C with.   replacem, monitor for sev.skin reacts.: with./permanent. discont.
                                48 hrs.not due to identifiab.cause/collapse or shock-like state/per-
   pertuss.cont.vaccin., progress. neurolog.disord./uncontrol epilep./   bas.on sev.& admin.corticoster.; permanent. discont. if SJS/TEN is
   progress.encephalopathy unt.treatm.regim.est./ condit.stabil./be-  sist.inconsolable cry.last.&gt;3 hrs. within 48 hrs.of vaccinat./convuls.  confirm., monit. for infus.-relat.reacts.; permanent.discont.if Grade
                                with/-out fev. within 3 days of vaccinat., consid.benef./risk in high
   nef.outweighs risk.          pertussis incid.& in childr.with progress. neurolog.disords., bleed.dis-  3/ 4 dev. , permanent.discont. if treatm.relat.toxic. not resolv. to
   Warnings: Hypersens.to glutaraldehyde/ formaldehyde/ neomycin/  ords., thrombocytopen., prev. neomycin/polymix.hypersens., monit.  Grade 0–1 within 12wks aft.last dos./ or inability to reduc.corticos-
   streptomycin/polymyxin B.    pts with hist. of febr.convuls.for 2-3 days, do not mix.in same syringe   ter.dos.to ≤10mg/ day of prednisone/equiv.within 12wks; perman.
   Side effects: Loc.reacts.incl.erythem./pain/ swell., irritabil., crying   with other vacc., safety in pregn.& lactat. not est.,ensure proced.in   discont.if anoth.episode of sev.tox.occ.urs /pts. with liv.metastas.
   incl.prolong., hypersens. reacts., anorex., somnol., hypoton.reacts.,   place to avoid injury from faint.as syncope.poss., poss.reduc. antibody   who begin treatm.with mod. (Grade 2) elev. of AST/ ALT if AST/
   vomit., diarrh., rash, pyrex., extens.limb swell., bleed., brach.neu-  respons.from immunosuppress.pts., insuff. data regard.concom.MMR   ALT incr. ≥ 50 % relat.to baseline & lasts ≥ 1 wk.
   rit.& Guillain Barre syndr.aft.tetanus tox.cont.vacc., oedemat.react.  vacc., low. immun. respons.poss.in prem.infts., apnoea risk/ need for   Drug interactions: Avoid use of system. corticoster./ immuno-
   of one/both low. imbs/ assoc.redn./cyanos./purpura/cry.poss.occur   48-72 hrs.monit.in very prem.infts.esp. those with prev.resp.imma-  suppress.bef. start.treatm. because of potent. interfer.with phar-
   aft.vaccin.with Hib cont.vacc., convuls.with/ without fev., periph.   turit.hist., high.fev.incid. with comcom.pneumocc.saccharid.conjug.  macodynam. activ. & effic.(may however be introd.later to treat
   neuropathy/opt.neurit./CNS demyelinat. aft.admin. of hepatit.B   adsorb. vacc., hepatit.D poss. prevent., bronchosp./ laryngeal oed.,   immune-mediat.S/E)
   antig.-cont. vacc.           fam.hist.of seiz.assoc.with incr. seiz. freq.follow.pertuss. immunisat.,
   Special precautions: Caut.in pts.with thrombocytopaen., bleed.  hepatit.B compon. of Hexa vacc.will not prev.against other hepatit.   MABTHERA, Roche [P/S]
   disord., in case of anaphylax.appropr.medic.treatm.& supervis.  strains/pathogens known to infect.liv., Hib compon. does not prev.  Rituximab.
   to be avail., eval.merits of subseq.dos.of pertuss.-contain. vacc.in   against.dis.due to other Haemophil. influenzae strains/meningit.  Indications: Relaps.or chemo-resist.low grade/ follicul./CD20-posit./
   case of prev.sympt.aft.receipt of vacc: temp.&gt;40°C with.48 hrs.not   caus.by other organ.  B-cell non-Hodgkin’s lymphoma, prev.untreat.pts.with stage III-IV fol-
   due to identif. cause/collapse or shock-like state/ persist. inconsol.   licul. lymphoma in combinat.with chemother., maint.treatm.in follicul.
   cry.last.&gt;3 hrs.within 48 hrs.of vaccin., convuls.with/-out fev.within   INTRAGAM, NBI [P/S]  lymphoma aft respons.to induct.ther., high grade CD20 posit.diffuse
   3 days of vaccinat., vacc.does not protect.against infect.dis.caus.by   Human normal immunoglobul.deriv.from human plasma, test.& found   large B-cell non-Hodgkin’s lymphoma in combin.with CHOP chem-
   other types of Hib/meningit.of other orig., no protect. to hepatit infect.  non-react.to HBsAg & antibodies to HCV, HIV-1 & HIV-2 viruses.  other., in combinat.with fludarabine & cyclophosphamide in prev.un-
   caus.by other agents except Hep B, immunogenicity poss.reduc.by   Indications: Pre-& post.expos.hepatit.A prophylax., substitut.& re-  treat.& relaps./ refract. chron.lymphocyt.leukaem., in combinat. with
   immunosuppress. ther./immunodefic., vaccin. recomm. in indiv.with   placement ther.in prim.& second. antibody defic.states.  methotrex.in adults with act.rheumat.arthrit. where respons.was in-
   chron.immunodefic.such as HIV infect., apnoea risk/need for 48-  (S4) IM INJ. T/30.2/740/741.  adeq./intol to dis.modify. anti-rheumat.drugs incl.one or more tumour
   72 hrs.monit. in very prem.infts.esp.those with prev.resp. immaturit.   731455-002: 16%, 1x2 ml, R124,13  necros. fact.inhibit.ther., severe.act.granulomatos. with polyangiitis
   hist., cons.benef.vs risk of tetanus toxoid-cont.vacc.if Guillan Barre   731463-005: 16%, 1x5 ml, R310,34  (GPA) & microscop.polyangiitis (MPA) in combinat.with glucocortic.
   syndr./brach. neurit. prev.occur.foll.receipt.  Dosage: Admin.IMI, div.large dos.betw.diff.sites. Admin.in.div.dos.  (S4) SOL FOR INFUS, 32/26/0578, 0579
                                at diff. sites if large vol. (&gt;2 ml for childr./&gt;5 ml for adults) reqd., do   853224-005: 100 mg, 2x 10 ml vials, R7 237,27
   HIBERIX, GSK [P/S]           not mix with other prods.     853232-008: 500 mg, 1x 50 ml vial, R18 093,29
   Haemophilus influenz. type b capsul.polysacchar. (PRP) conjugat.  Hepatit.A prophylax: Pre-expos.travellers to endem.areas:   For further details refer to manufact.prod.lit.
   to tetanus tox               0,02 ml/kg if visit. less than 3 mnths.0,06 ml/kg 4-6 mnthly.if visit con-
   Indications: Act.haemophilus influenz.type b (Hib) immunisat.  tin. Post expos.within 1 wk of household contact: 0,02-0,04 ml/kg  MEASBIO, Biovac [P/S]
   in infts.≥ 6 wks.            Replacement ther: Congenit.immunoglobul. defic: 0,2-0,5 ml/  Live attenuat.measles virus prepared. in SPF chick. embryo. Residual
   (S2) POWD FOR INJ. 32/30.1/0349. 10 µg/0,5 ml  kg repeat 4-8 wkly. Trans. hypogammaglobulinaem: 0,2-0,5 ml/  Kanamycin & erythromycin.
   700767-001: 1x3 ml vial, R177,92  kg rep. when necess.     Indications: Act.measles immunisat.</code></pre>
     	</div>
    
     </div>
     <div id="content-bottom">
       <div id="content-bottom2">
         <table width="110" border="0" cellspacing="0" cellpadding="0">
           <tr>
             <td width="22%" height="44"><a href="page372.html"><img src="images/previous.png" width="26" height="19" id="Image2" onmouseover="MM_swapImage('Image2','','images/previous2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
             <td width="43%">
             	&nbsp;&nbsp;&nbsp;<a href="page368.html">368</a>&nbsp;&nbsp;&nbsp;<a href="page369.html">369</a>&nbsp;&nbsp;&nbsp;<a href="page370.html">370</a>&nbsp;&nbsp;&nbsp;<a href="page371.html">371</a>&nbsp;&nbsp;&nbsp;<a href="page372.html">372</a>&nbsp;&nbsp;&nbsp;<a href="page373.html">373</a>&nbsp;&nbsp;&nbsp;<a href="page374.html">374</a>&nbsp;&nbsp;&nbsp;<a href="page375.html">375</a>&nbsp;&nbsp;&nbsp;<a href="page376.html">376</a>&nbsp;&nbsp;&nbsp;<a href="page377.html">377</a>&nbsp;&nbsp;&nbsp;<a href="page378.html">378</a>
             </td>
             <td width="35%"><a href="page374.html"><img src="images/next.png" width="26" height="19" id="Image1" onmouseover="MM_swapImage('Image1','','images/next2.png',1)" onmouseout="MM_swapImgRestore()" /></a></td>
           </tr>
         </table>
       </div>
     </div>
  </div>
</div>
<div id="right-button">
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p>&nbsp;</p>
  <p><a href="page374.html"><img src="images/next_big.png" width="90" height="80" /></a></p>
</div>


</div>

</body>
</html>
